Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Extended Interval Dosing of Natalizumab in RRMS
NCT04225312Phase 4Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Amsterdam University Medical Center. Status: unknown.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04225312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225312.